The Midwest might not have as much funding activity as some parts of the West Coast or other established hotbeds for innovation, but potential med-tech entrepreneurs and would be investors would be foolish to overlook this region, according to a report from BioEnterprise. The med-tech companies are consistently finding funding in the Midwest, and were even able to raise dollars during the tumultuous years following the economic meltdown. Since I began my tenure at Medical Device Daily in 2007, the region has produced strong numbers consistently. The study points out that Midwest healthcare companies attracted $1.8 billion in new investments...
Medtronic (Minneapolis) reported the start of the global launch of the MiniMed 640G System, the next breakthrough toward an artificial pancreas. With the introduction of Medtronic's exclusive SmartGuard technology, MiniMed 640G is designed to help people with diabetes achieve better glucose control through advanced protection from hypoglycemia. The system both automatically suspends insulin delivery when sensor glucose levels are predicted to approach a low limit and resume insulin delivery once sensor glucose levels recover.
Transcatheter mitral valve implantation (TMVI) is the next frontier for structural heart therapy. It is expected to revolutionize the way of treating mitral valve insufficiency. Approximately 3% of the population older than 60 years is suffering from symptomatic mitral valve regurgitation and may benefit from this interventional procedure while avoiding open-heart surgery
